2003 Disease Trials Vaccine 
Drug Discovery World
MAY 15, 2024
Researchers have developed a new vaccine technology that can provide protection against a broad range of coronaviruses with potential for future disease outbreaks – including ones we don’t know about yet. Building protective vaccines before a pandemic emerges “We don’t have to wait for new coronaviruses to emerge.
PLOS: DNA Science
JULY 27, 2023
That information led, thanks to vaccine shelved from the first SARS circa 2003, to the rapid development and deployment of mRNA vaccines against the new infectious disease. Next up: testing in real-world settings and submission of clinical trial findings to the FDA.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
JULY 22, 2021
NOTE: ADUHELM TM (aducanumab-avwa)injection 100 mg/mL solutionis indicated for the treatment of Alzheimer’s disease. Treatment with ADUHELM should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials. Biogen Inc.
The Pharma Data
DECEMBER 23, 2020
Eligible patients enrolled in the trial receive treatment with AIM’s flagship pipeline drug Ampligen. The Ampligen EAP protocol is authorized to enroll up to 100 active trial participants, 20 of whom may be Long Haulers. Centers for Disease Control and Prevention’s criteria for chronic fatigue syndrome. See: PLOS ONE ).
The Pharma Data
FEBRUARY 12, 2022
The BLISS-LN phase III trial is the largest and longest trial conducted in active LN, involving 448 adult patients. Belimumab is also approved in China for five-year-old and older patients with active, autoantibody-positive SLE with high disease activity (e.g., About the BLISS-LN trial. About lupus.
NIH Director's Blog: Drug Development
MAY 21, 2020
Science, 2020 We now know that the immune system of nearly everyone who recovers from COVID-19 produces antibodies against SARS-CoV-2, the novel coronavirus that causes this easily transmitted respiratory disease [1]. In the U.S. Collins FS, Stoffels P. 2020 May 18.
NIH Director's Blog: Drug Development
MARCH 18, 2021
He uses these fundamental insights to guide the design of vaccines and therapeutics, including promising monoclonal antibodies. He’s also a member of the international research team that identified a human antibody, called S309, from a person who’d been infected with SARS in 2003.
Expert insights. Personalized for you.
130 
Let's personalize your content